Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Somatropin (recombinant human growth hormone) binds to GH receptors, stimulating IGF-1 production in the liver and peripheral tissues. IGF-1 drives anabolic processes including protein synthesis, lipolysis (fat breakdown), and bone mineralization.
Commercial somatropin is FDA-approved at fixed doses for defined indications. Compounded HGH allows customized doses for adult GH deficiency optimization and combination with peptides or hormones in protocols not commercially available.
Compare up to 7,500 pharmacies across the USA.
Human growth hormone (somatropin) is produced by the pituitary gland and plays central roles in growth, metabolism, body composition, and cellular repair. GH secretion declines significantly with age (somatopause), contributing to increased body fat, reduced muscle mass, decreased bone density, and impaired quality of life.
Compounded HGH is used by physicians in adult GH deficiency protocols. Multiple FDA-approved brands exist; compounded versions offer customized dose flexibility and combination with sermorelin or GHRP peptides for optimized GH axis support.
GH Receptor Activation
Somatropin binds to dimeric GH receptors on the surface of target cells including hepatocytes, adipocytes, and muscle cells. Receptor activation triggers the JAK-STAT signaling pathway, leading to transcription of IGF-1 and other GH-responsive genes.
IGF-1 Mediated Effects
Hepatic IGF-1 production (stimulated by GH) mediates most of the anabolic effects — protein synthesis, cellular proliferation, and bone growth. IGF-1 also has direct effects on muscle and fat tissue.
Direct Lipolytic Action
GH directly stimulates lipolysis in adipose tissue through hormone-sensitive lipase activation, independent of IGF-1 — increasing free fatty acid release from adipocytes and driving fat oxidation.
Adult growth hormone deficiency (AGHD), body composition optimization (muscle/fat ratio), anti-aging and longevity protocols, recovery from surgery or illness, bone density support, combination GH optimization protocols
Pediatric GH deficiency (FDA-approved), Turner syndrome, Prader-Willi syndrome, short bowel syndrome, HIV-associated wasting (Serostim), idiopathic short stature, post-surgical recovery (off-label), chronic kidney disease-associated growth failure
Adult GHD replacement: 0.2–0.5mg SubQ daily, titrated to IGF-1 levels
Optimization protocols: 0.1–0.3mg SubQ daily or rotating schedules
Administration: Evening injection recommended to mimic physiologic GH pulse
Monitoring: IGF-1, fasting glucose every 3–6 months
Begin at a low dose (0.1–0.2mg/day) and titrate up by 0.1–0.2mg every 4–8 weeks based on IGF-1 response and symptom tolerance. Target IGF-1 in the mid-normal range for age and sex. Evening administration mimics the physiologic nocturnal GH pulse. Rotate injection sites to prevent lipodystrophy.
SubQ Injectable (multi-dose vial) — reconstituted lyophilized powder; refrigerated after reconstitution; typical shelf life 28 days after mixing
SubQ Injectable (single-dose) — pre-filled or unit-dose preparations for travel or dosing precision
Custom Dose Vials — compounded at precise concentrations to allow accurate low-dose administration during initial titration
Fluid retention, joint/muscle pain, carpal tunnel syndrome (often dose-dependent and transient). Potential glucose dysregulation. Theoretical cancer risk with supraphysiologic doses. Contraindicated in active malignancy. Requires careful dose titration and monitoring.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
